14 results on '"Bavbek S"'
Search Results
2. Omalizumab in non-allergic Asthma: A report of 13 cases.
- Author
-
Çelebi Sözener Z, Aydın Ö, Mısırlıgil Z, Mungan D, Demirel YS, Çelik GE, Sin BA, and Bavbek S
- Subjects
- Adult, Asthma diagnosis, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Respiratory Function Tests, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Anti-Asthmatic Agents administration & dosage, Asthma drug therapy, Omalizumab administration & dosage
- Abstract
Background: There are limited data regarding the effectiveness of omalizumab in patients with non-allergic asthma., Objective: To evaluate the clinical and functional effectiveness of omalizumab in patients with non-allergic asthma., Methods: The study was a single-center, retrospective chart review of patients with non-allergic asthma who were treated with add-on omalizumab between February 2014 and March 2016. After omalizumab was started, data of the asthma control test (ACT), pulmonary function test, and daily oral corticosteroid (OCS) dosage were collected at baseline, 16 weeks, 1 year, 2 and 3 years (if available). The number of exacerbations/hospitalizations were collected 1 year prior to and 6 months/1 year after omalizumab. To calculate the total daily dosage of OCS in milligrams, data for 6 months/1 year prior and after omalizumab treatment were recorded., Results: Thirteen patients were included. After omalizumab, the mean ACT was significantly increased at 16 weeks (n = 13, p = 0.002), 1 year (n = 7, p = 0.006), and 2 years (n = 5, p = 0.006). The mean daily OCS dose was significantly decreased at 16 weeks (n = 13, p = 0.001), 1 year (n = 7, p = 0.006), and 2 years (n = 5, p = 0.04). The mean number of exacerbations and hospitalizations were decreased at the 6th month (n = 13; p = 0.001, p = 0.005) and 1st year (n = 7; p = 0.01, p = 0.02). The mean total quantity of OCS decreased 42% from 1.4 to 0.8 g in the six-month period prior to and post-omalizumab treatment (n = 6, p = 0.02) and decreased 76% from 3.8 to 0.9 g at 1 year in the pre vs. post-omalizumab treatment comparison (n = 7, p = 0.01). Six (46.2%) patients responded perfectly and seven (53.8%) partially responded to treatment., Conclusion: Omalizumab can be effective in non-atopic severe asthma.
- Published
- 2018
- Full Text
- View/download PDF
3. Does the medical diagnosis of occupational asthma coincide with the legal diagnosis?
- Author
-
Çelebi Sözener Z, Aydın Ö, Demirel YS, Soyyiğit Ş, Çerçi P, Kendirlinan R, Bavbek S, Çelik GE, Misirligil Z, Sin BA, Keleşoğlu A, and Mungan D
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Reproducibility of Results, Retrospective Studies, Asthma, Occupational diagnosis, Disability Evaluation, Occupational Health legislation & jurisprudence
- Abstract
Objective: The incidence of occupational asthma (OA) is increasing worldwide. In this study, we first aimed to document the rate of diagnosis of OA among patients who were referred to our clinic from the Social Security Institution and the factors that affected diagnosis; secondly, we aimed to assess the consistency of the medical and legal diagnoses., Methods: The study involved 132 consecutive patients who were referred to our clinic for the evaluation of OA between 2010 and 2015. Detailed workplace history, the tools used in the diagnosis such as peak expiratory flow (PEF) monitoring and bronchial provocation tests, and the final medical diagnosis were recorded from case files., Results: Asthma was diagnosed in 75% (n = 99) of the patients. Among them, 22.2% were diagnosed as having OA. The diagnosis was confirmed by serial PEF measurements, non-specific bronchial hyperreactivity assessment or both of the tests both at work and off-work periods. OA diagnosis was mostly established in active workers (72.7%). The legal diagnosis period was completed in 54.5% of these 22 patients, and 50% (n = 11) were officially diagnosed as having OA with a 91.6% concordance with medical diagnosis., Conclusion: This study verifies the importance of diagnosing asthma correctly as a first step in the evaluation of OA. Diagnostic tests other than specific provocation tests could be preferential in patients who still work in the same field. We believe that cooperation with the patient's occupational physician and adequate recognition of the work environment will improve the consistency of legal and medical diagnoses.
- Published
- 2017
- Full Text
- View/download PDF
4. Survey of physicians' attitudes toward the use of magnesium sulfate for acute asthma exacerbations in Turkey.
- Author
-
Baççıoğlu A, Bakırtaş A, Öner Erkekol F, Kalaycı Ö, and Bavbek S
- Subjects
- Acute Disease, Adult, Anti-Asthmatic Agents adverse effects, Female, Health Knowledge, Attitudes, Practice, Humans, Magnesium Sulfate adverse effects, Male, Middle Aged, Surveys and Questionnaires, Turkey, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy, Attitude of Health Personnel, Drug Utilization statistics & numerical data, Magnesium Sulfate therapeutic use, Physicians statistics & numerical data
- Abstract
Background: Magnesium sulfate (MgSO4) is considered to be a well-tolerated, inexpensive, and effective medication for severe asthma exacerbations. We surveyed physicians who treat patients with asthma to evaluate the current knowledge and usage of MgSO4., Methods: A self-administered questionnaire was e-mailed to members of the Turkish National Society of Allergy and Clinical Immunology and was distributed to participants of its annual congress., Results: Of the 456 respondents (mean age: 36.53 ± 9.11 years), 42.3% reported to use MgSO4 in asthma exacerbations in their practice, and 48.7% agreed that MgSO4 was included in asthma guidelines. The best known indication was that it was useful only in patients refractory to bronchodilators and systemic corticosteroids (67.7%). The two most common reasons to use MgSO4 were to shorten hospital stay (94.7%), and prevent admission to intensive care unit (80.3%). The respondents mostly used MgSO4 in the treatment of severe or life-threatening exacerbations. Thirty-nine percent believed that MgSO4 had no effect on discharge period, and 29% of them marked minor side effects. The most common reason for not using MgSO4 was inexperience (36.5%). Having an academic affiliation (OR = 3.20, p < 0.001), the number of asthmatic outpatients seen per month (OR = 1.82, p = 0.007), and more recent graduation from medical school (≤1991) (OR = 0.23, p < 0.001) were associated with the use of MgSO4 in the multivariate analysis., Conclusion: Even though the effect of MgSO4 in acute severe asthma is well known, only half of the physicians dealing with asthma patients have used it in their practice. Education and encouragement in this regard are necessary.
- Published
- 2016
- Full Text
- View/download PDF
5. Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.
- Author
-
Vrdoljak E, Torday L, Szczylik C, Kharkevich G, Bavbek S, and Sella A
- Subjects
- Carcinoma, Renal Cell pathology, Cost-Benefit Analysis, Economics, Pharmaceutical, Europe, Eastern, Humans, Kidney Neoplasms pathology, Reimbursement Mechanisms, Turkey, Antineoplastic Agents economics, Antineoplastic Agents therapeutic use, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell economics, Kidney Neoplasms drug therapy, Kidney Neoplasms economics
- Abstract
Introduction: The incidence and mortality rates of kidney cancer in the Central and Eastern European (CEE) region are among the highest in the world. Access to second and subsequent lines of metastatic renal cell carcinoma (mRCC) therapies is highly varied in the region. Despite the increasing body of evidence supporting the clinical benefit of multiple lines of treatment, access to treatment beyond first line is restricted in many of these countries., Areas Covered: The adoption of targeted therapies for the first-line treatment of mRCC in the region was slow and faced many obstacles. In order to evaluate the current status of treatment beyond the first-line setting in the CEE region, this review examines the availability and reimbursement of mRCC drugs and clinical practice in institutions that treat patients with mRCC., Expert Opinion: This review highlights the need to raise awareness among physicians, payers and regulators on clinical trial and cost-effectiveness data regarding the treatment of mRCC beyond the first line. The obstacles to mRCC drug access highlighted in this review need to be overcome to ensure that patients are receiving the best treatment available.
- Published
- 2016
- Full Text
- View/download PDF
6. Is there any difference in the use of complementary and alternative therapies in patients asthma and COPD? A cross-sectional survey.
- Author
-
Argüder E, Bavbek S, Sen E, Köse K, Keskin O, Saryal S, and Misirligil Z
- Subjects
- Aged, Consumer Health Information, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Prevalence, Severity of Illness Index, Sex Factors, Socioeconomic Factors, Turkey, Asthma therapy, Complementary Therapies statistics & numerical data, Pulmonary Disease, Chronic Obstructive therapy
- Abstract
Background: Data on the use and efficacy of complementary and alternative medicine (CAM) in patients with asthma are limited, and there is a lack of studies documenting the use of CAM in patients with chronic obstructive pulmonary disease (COPD) in Turkey., Aim: To determine the prevalence of CAM usage in patients with asthma and COPD and to assess the clinical and demographic factors associated with the use of CAM., Materials and Methods: A total of 521 patients (313 with asthma and 208 with COPD) were randomly enrolled into this cross-sectional survey. A face-to-face interview was conducted using a structured questionnaire., Results: One hundred sixty-three patients (52%) with asthma and 70 patients (33%) with COPD were reported to be using some form of CAM (p < 0.001). The most popular modalities were herbal remedies (46% and 28% in the two groups, respectively) and animal products (28% and 5% in the two groups, respectively). CAM-practicing asthma patients were typically younger with longer duration of disease and higher income than the CAM-practicing COPD patients. For the patients, the main source of information on CAM practices was their relatives and friends. Only a small number of the patients consulted with their physicians about CAM. The main reasons to use CAM for patients with asthma and COPD were harmlessness and symptomatic relief, respectively. CAM-related adverse effects and difficulties to obtain CAM were significantly higher in patients with asthma than in patients with COPD., Conclusion: There is a high prevalence of CAM usage in patients with asthma and COPD in Turkey. Hence, becoming familiar with CAM therapy and inquiring about patient practice of CAM as part of the routine medical history will allow the physicians to provide reliable information to their patients on these medical practices.
- Published
- 2009
- Full Text
- View/download PDF
7. Sensitization to Alternaria and Cladosporium in patients with respiratory allergy and outdoor counts of mold spores in Ankara atmosphere, Turkey.
- Author
-
Bavbek S, Erkekol FO, Ceter T, Mungan D, Ozer F, Pinar M, and Misirligil Z
- Subjects
- Adolescent, Adult, Child, Colony Count, Microbial, Female, Humans, Male, Middle Aged, Alternaria immunology, Asthma etiology, Cladosporium immunology, Rhinitis, Allergic, Perennial etiology, Rhinitis, Allergic, Seasonal etiology, Spores, Fungal immunology
- Abstract
Sensitization to Alternaria and Cladosporium has been reported to be 3% to 30% in European countries. However, in Turkey, there is limited data about the prevalence of sensitization to these molds and the intensity of the two mold spores in Ankara atmosphere. This study was designed to evaluate the sensitization to Alternaria and Cladosporium in patients with respiratory allergy in Ankara and also the concentration of the two molds in Ankara atmosphere. Allergic rhinitis and asthma patients living in Ankara were included in the study. Demographic and diagnostic data of the patients were recorded. A skin prick test with extracts supplied by three different laboratories was used to evaluate the sensitization to Alternaria and Cladosporium. Mold spores were measured using a Burkard 7-day recording volumetric spore trap in Ankara atmosphere during a year. Overall sensitization to the two molds was found to be 14.8%, and isolated Alternaria or Cladosporiumsensitization was 3%. Considering the positive reaction to at least one of the three suppliers, the sensitization rate was 11.9% and 8.1% for Alternaria and Cladosporium, respectively. Cochran's Q homogenization test demonstrated that the positive and negative reaction were not homogeneous among three laboratories. The total number of mold spores in Ankara atmosphere was 429,264 spores/m3 of which 75.5% and 6% were constituted by Cladosporium and Alternaria, respectively. The prevalence of Cladosporium and Alternaria sensitization in respiratory allergy patients is quite similar to European countries; however, our data indicate that commercial mold extracts should be standardized to establish the real sensitization rates. Additionally, considering the great numbers of these mold spores in Ankara atmosphere, long-term follow-up studies are needed to evaluate the relationship between the mold load and sensitization patterns.
- Published
- 2006
- Full Text
- View/download PDF
8. Allergy to drugs: is there an association with mental ill-health?
- Author
-
Bavbek S, Pasaoglu G, Canat S, Sagduyu G, and Misirligil Z
- Abstract
Objectives. Hypersensitivity reactions to drugs are not infrequent. A certain of anxiety, aggression or depression should be expected in patients with drug allergies, as they could experience symptoms ranging from mild to life-threatening reactions following consumption of drug. However, a literature search resulted in very limited data. This study was designed to evaluate the psychological status of patients with drug allergy and to assess the relationships between psychological evaluations of the patients and, duration of drug allergy, type of allergic reaction, hypersensitivity reaction of the type of drug involved. Methods. The study group comprised 61 patients (43 F, 18 M), age ranging from 16 to 75 years, with reliable history of drug allergy. A total of 55 healthy subjects (39F, 16M) age ranging from 17 to 70 years served as control group. Assessment tools consisted of Beck Depression Inventory (BDI), and Speilberger's State-Trait Anxiety Inventory (STAI Tx-2). Results. The prevalence of depression and anxiety among patients with drug allergies was not greater than that of the controls. There were no associations between the scores of these psychological assessments and duration of drug allergy, type of allergic reaction, type of drug. Conclusions. Our data suggest that follow-up studies including high numbers of patients and patients with specific and potentially life-threatening clinical pictures of drug allergies are needed to detect clinically relevant associations.
- Published
- 2006
- Full Text
- View/download PDF
9. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance.
- Author
-
Celik G, Paşaoğlu G, Bavbek S, Abadoğlu O, Dursun B, Mungan D, and Misirligil Z
- Subjects
- Adult, Anaphylaxis chemically induced, Bronchial Spasm chemically induced, Celecoxib, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Female, Humans, Male, Membrane Proteins, Rhinitis chemically induced, Single-Blind Method, Treatment Outcome, Urticaria chemically induced, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Aspirin adverse effects, Cyclooxygenase Inhibitors therapeutic use, Drug Hypersensitivity, Prostaglandin-Endoperoxide Synthases drug effects, Pyrazoles therapeutic use, Sulfonamides therapeutic use
- Abstract
Intolerance reactions to acetyl salicylic acid (ASA) and nonsteroidal anti-inflammatory drugs (NSAIDs) are common and caused by inhibition of COX-1 enzyme. Therefore, drugs that selectively inhibit COX-2 enzyme may be safe in these subjects. In this study, we evaluated the tolerability of celecoxib, a selective COX-2 inhibitor, in patients with analgesic intolerance. The eligible study population consisted of patients with a history of urticaria/angioedema, naso-ocular symptoms, bronchospasm, and/or anaphylactoid reaction induced by ASA and/or NSAIDs. A single-blind, placebo-controlled oral challenge test was performed in the hospital setting. On 2 separate days, 1/4 and 3/4 divided doses of placebo and celecoxib (Celebrex 200 mg, Pfizer, Turkey) were given with 2-hour intervals. Seventy-five subjects (mean age: 38.2 +/- 1.4 years; F:M: 55:20) were included in the study. Twenty-one subjects had asthma. No reaction was observed with placebo or celecoxib provocation. Although celecoxib seems to be a safe alternative drug in our study group, considering its serious adverse events reported in the literature, the drug should be recommended for patients with analgesic intolerance only after being tested by an experienced allergist.
- Published
- 2005
- Full Text
- View/download PDF
10. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
- Author
-
Bavbek S, Celik G, Ozer F, Mungan D, and Misirligil Z
- Subjects
- Adolescent, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Aspirin adverse effects, Asthma chemically induced, Female, Humans, Immunologic Tests methods, Male, Meloxicam, Middle Aged, Single-Blind Method, Sulfones, Treatment Outcome, Urticaria chemically induced, Cyclooxygenase Inhibitors adverse effects, Drug Hypersensitivity etiology, Lactones adverse effects, Sulfonamides adverse effects, Thiazines adverse effects, Thiazoles adverse effects
- Abstract
Background: Intolerance to acetylsalicylic acid (ASA) and other nonsteroidal anti-inflammatory drugs (NSAIDs) is a crucial problem in clinical practice. There is, therefore, a need for safer NSAIDs in patients with analgesic intolerance., Objective: To assess the safety of nimesulide, meloxicam, and rofecoxib, selective COX-2 inhibitors, in a group of ASA/NSAIDs-intolerant patients., Method: Tolerances to nimesulide, meloxicam, and rofecoxib were assessed by single-blind placebo-controlled oral challenges. One hundred twenty-seven subjects with history of adverse reaction to ASA/NSAIDs received oral challenges with nimesulide, 61 subjects were challenged with meloxicam, 51 subjects were challenged with rofecoxib, and 37 subjects were challenged with all three drugs. Placebos were given to all patients on the first day of the study. On the second day, one-fourth and three-fourths of the therapeutic doses of the active drugs (nimesulide 100 mg, meloxicam 7.5 mg, or rofecoxib 25 mg) were given at 60-minute intervals. There was at least a 3-day interval between challenge tests. Erythema, pruritus accompanied by erythema, urticaria/angioedema, rhinorrhea, nasal obstruction, sneezing, dyspnea, or cough associated with a decrease of at least 20% in the forced expiratory volume (FEV1) and hypotension were considered as positive reactions., Results: Positive reactions to the nimesulide, meloxicam, and rofecoxib challenges were observed in 18/127 (14.3%), 5/61 (8.1%), and 1/51 (2.0%) patients, respectively. In each group of nine patients, there were two patients with asthma and four who developed skin type reactions and asthmatic reactions, respectively, to the nimesulide challenge. Among five patients who reacted to the meloxicam challenge, asthmatic type reactions were detected in two asthmatics. Only one urticarial type reaction was observed with rofecoxib challenge in one patient who presented with anaphylaxis to ASA/NSAIDs. All patients with asthma tolerated rofecoxib without any adverse effects. None of the patients reacted to the placebo. Among 37 patients challenged with all three drugs, 11 reacted to nimesulide, and one patient reacted only to meloxicam. Three patients reacted to more than one of the drugs tested, and one of them reacted to all drugs., Conclusion: This is the first placebo-controlled report comparing these three drugs. The results indicate that among these alternative drugs for ASA/NSAIDs-intolerant patients, rofecoxib seems to have the most favorable tolerability.
- Published
- 2004
- Full Text
- View/download PDF
11. Risk factors determining allergic airway diseases in Turkish subjects.
- Author
-
Celik G, Sin B, Keskin S, Ediger D, Bavbek S, Mungan D, Ozer F, Demirel YS, Gürbüz F, and Misirligil Z
- Subjects
- Adult, Cross-Sectional Studies, Female, Humans, Hypersensitivity diagnosis, Life Style, Male, Multivariate Analysis, Risk Factors, Rural Population, Skin Tests, Turkey, Urban Population, Hypersensitivity complications, Respiratory Tract Diseases etiology
- Abstract
With regard to changes in life-style after the 1980s, the reflection of environmental factors on the evolution of allergic airway disease (AAD) has not yet been analyzed in Turkey. In this trial, we aimed to determine the factors related to AAD in Turkish subjects. Patients diagnosed as having asthma and/or rhinitis with positive skin prick tests (SPTs) were accepted as members of the "atopic group" (n = 235). Subjects demonstrated to have negative SPTs and no clinical evidence of any atopic disorder were accepted as members of the "nonatopic control group" (n = 84). Data obtained from a questionnaire applied cross-sectionally to the study groups were compared for risk factor analysis. According to the results of univariate analysis, nonatopic controls were found to have been born in villages more frequently than those in the atopic group (14.3% vs. 4.7%, p = 0.02). Atopic group members had lived in apartments during childhood more frequently than nonatopic controls (53.6% vs. 38%, p = 0.04). A topic group members, particularly the asthmatics, had lower sibship size (< or = 1 sibling) (41.3% vs. 16.7%, p = 0.0003) and nonatopic subjects had higher sibship size (> or = 3 siblings) (73.8% vs. 43.4%, p < 0.0001). The rate of maternal atopy was higher in the atopic group (24.7% vs. 9.5%, p = 0.02). Place of birth, sibship size, and atopic status of the mother, but not house type, were found to be significant in the multivariate analysis. As a conclusion, rural life-style seems to have a protective effect on the development of atopy in Turkey. On the contrary, factors directly or indirectly related to urban life-style during early childhood were found to be associated with the allergic airway diseases.
- Published
- 2002
- Full Text
- View/download PDF
12. Clinical features and atopy profile in Turkish subjects with analgesic intolerance.
- Author
-
Celik G, Mungan D, Ozer F, Ediger D, Bavbek S, Sin B, Demirel YS, and Misirligil Z
- Subjects
- Acetaminophen adverse effects, Acetaminophen immunology, Adolescent, Adult, Aged, Analgesics, Non-Narcotic adverse effects, Analgesics, Non-Narcotic immunology, Anti-Bacterial Agents immunology, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Anti-Inflammatory Agents, Non-Steroidal immunology, Aspirin adverse effects, Aspirin immunology, Asthma etiology, Drug Hypersensitivity complications, Drug Hypersensitivity diagnosis, Female, Humans, Male, Middle Aged, Skin Tests, Turkey, Analgesics adverse effects, Analgesics immunology, Drug Hypersensitivity physiopathology
- Abstract
The factors underlying analgesic intolerance (AI), particularly the role of ethnic characteristics, are readily not clear. In this trial, we aimed to assess the predictive features of AI in Turkish subjects. One hundred and ninety patients with AI were enrolled into the study conducted in our tertiary care clinic. The types of drug causing adverse reaction(s) and types of reaction(s) were recorded. The presence of atopy was assessed by skin prick tests. According to the results, the most frequently intolerated analgesic was acetyl salicylic acid (72.1%), followed by nonsteroidal anti-inflammatory drugs (68.4%) and paracetamol (15.8%). Urticaria/angioedema (52.6%) and asthmatic response (40.5%) were the most common reactions to analgesics. Compared with the general adult population of Turkey, the rate of atopy was found be higher in patients with AI and asthma (25% vs. 45%, p = 0.004) but comparable in patients with AI but no atopic disorder (25% vs. 29.2%, p> 0.05). In conclusion, subjects exhibiting intolerance to analgesics have particular features in our population; the presence of atopy in these subjects seems to be associated with the coexistent asthma rather than the drug allergy itself.
- Published
- 2002
- Full Text
- View/download PDF
13. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance.
- Author
-
Bavbek S, Celik G, Ediger D, Mungan D, Demirel YS, and Misirligil Z
- Subjects
- Administration, Oral, Adult, Aged, Angioedema chemically induced, Asthma chemically induced, Cyclooxygenase Inhibitors adverse effects, Female, Humans, Male, Middle Aged, Prevalence, Rhinitis chemically induced, Single-Blind Method, Skin Tests, Sulfonamides adverse effects, Urticaria chemically induced, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Aspirin adverse effects, Cyclooxygenase Inhibitors therapeutic use, Drug Hypersensitivity diagnosis, Drug Hypersensitivity epidemiology, Sulfonamides therapeutic use
- Abstract
Intolerance or idiosyncrasy to acetylsalicylic acid (ASA) and other nonsteroidal anti-inflammatory drugs (NSAIDs) is a crucial problem because these drugs are frequently used in medical treatment. In this study, we tested whether nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, might be a valid alternative for patients with histories of adverse reaction to ASA or NSAIDs. A single-blind, placebo-controlled oral challenge procedure was applied to 60 adult patients (19 male, 41 female; with a mean age of 40.31 +/- 10.44 years, range 20-68 years) with a reliable history of ASA/NSAIDs-intolerance. According to history, the clinical presentations of intolerance were urticaria/angioedema in 32 patients, anaphylactoid reaction in 2 patients, respiratory reaction in 19 patients, and respiratory and cutaneous reaction in 7 patients. Atopy was confirmed by means of skin prick test with inhalant allergens. Oral challenge protocol was started with 25 mg of nimesulide and the remaining 75 mg was given 1 hr later. During the challenge procedure, blood pressure, pulse, nasoocular, pulmonary, and cutaneous symptoms were monitored. Of the 60 patients tested, 55 (91.7%) tolerated the drug with no adverse reaction. Only five (8.3%) patients demonstrated a positive response to oral challenge. The clinical presentations of intolerance to nimesulide were urticaria/angioedema in three patients, mild rhinitis in one patient, and mild dyspnea in one patient. The atopy prevalence was higher, with a ratio of 41.7%, in patients with ASA/NSAIDs intolerance than that of the healthy adult population in Turkey (p < 0.05). We believe that nimesulide can be used as an alternative drug for patients with ASA/NSAIDs intolerance.
- Published
- 1999
- Full Text
- View/download PDF
14. The prevalence of allergic diseases and atopy in Ankara, Turkey: a two-step population-based epidemiological study.
- Author
-
Celik G, Mungan D, Bavbek S, Sin B, Ediger D, Demirel Y, and Misirligil Z
- Subjects
- Adolescent, Adult, Aged, Case-Control Studies, Cross-Sectional Studies, Female, Humans, Hypersensitivity diagnosis, Hypersensitivity immunology, Male, Middle Aged, Prevalence, Risk Factors, Surveys and Questionnaires, Turkey, Hypersensitivity epidemiology
- Abstract
To assess the prevalence of allergic diseases and atopy in adults, a two-step population-based epidemiological study was undertaken in Ankara, the capital city of Turkey. In step 1, a screening questionnaire adapted from the European Community Respiratory Health Survey (ECRHS) was applied in a cross-sectional manner. In step 2, a nested case-controlled design study was conducted and subjects were evaluated in the clinical setting for history, physical examination, skin prick tests (SPTs), and serum total IgE and phadiotop measurements. According to the results, self-reported current asthma prevalence in step 1 was lower compared with that in step 2 (3% vs. 7%, p < 0.05). The prevalences of food and drug allergy were 6.2% and 3.9%, respectively, in step 1, but were not demonstrated in any of the subjects in step 2. The overall prevalence of atopy was 25% after step 2 evaluation. In conclusion, allergic disorders are not uncommon in our adult population; however, sole application of a screening questionnaire appeared to be ineffective in revealing the accurate figures of asthma, and food or drug allergy.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.